Hide Board Information

Show Board Information

GE CAPITAL EUROPEAN FUNDING 2.875% NTS 28/10/14 EUR1000 61GX

Board Mod: Add me as mod

Asst Mods:

Last Post: 06/04/2012 2:03:26 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 1

GE CAPITAL EUROPEAN FUNDING 2.875% NTS 28/10/14 EUR1000 (61GX) Stock Message Board

Find 61GX Recent News, 61GX Filings, 61GX Stock Quote, 61GX Stock Chart, 61GX Research & Opinions Below

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

Be the first to post on GE CAPITAL EUROPEAN FUNDING 2.875% NTS 28/10/14 EUR1000 61GX

Recent Articles

• atNorth Welcomes New Directors to Enhance Sustainability and Culture
• Cinema Lenses Market Growth: A Closer Look at Future Trends
• Morpheus Unveils $20 Million Rewards for AI Compute Providers
• Understanding the Importance of Device Security in Today's World
• Join SkiStar AB's Upcoming Conference Call on Q1 Results
• Wolters Kluwer's Share Buyback Program Progress in 2024
• DFDS Impressive Ferry Growth in November Volumes Report
• PUMA Launches Innovative Studio48 to Transform Design Strategy
• DFDS Reports Strong Growth in Ferry Freight and Passengers
• Eviden Recognized for Leadership in AI and Data Solutions
• Exploring the Future of Digital Pathology with AI Integration
• Siemens Partners with Roboverse to Transform Inspection Services
• Insights into Tech Graduates' Career Aspirations in 2024
• Aon's Innovative War Risk Insurance Facility for Ukraine
• MYCOM OSI and Globe: Pioneering Innovation in Telecom Automation
• Yasmina Hayek: Celebrated Chef Nabs MENA's Top Culinary Award
• SPIC's Impressive Showcase at the China International Import Expo
• Macao's New Chief Executive Commits to Economic Diversification
• Innovative AND017 Shows Promise for Sickle Cell and More
• 51Talk Online Education Group Set to Announce Q3 Results Soon
• Equiduct Expands Offerings with iBroker Partnership Boost
• Equiduct Expands Pan-European Trading with iBroker Partnership
• WuXi Biologics: Leading the Way in Sustainable Development Initiatives
• General Inception and Enable Medicine Combine Forces for AI-driven Drug Discovery
• Neuraxpharm and Pharmathen Collaborate on Injectable Therapies
• SpliceBio's Breakthrough Drug SB-007 Receives FDA IND Clearance
• Business of Design Week 2024: A Celebration of Innovation
• Isotopia's Innovative Partnership Enhances Lupus Treatment Potentials
• HDI Global Welcomes Dr. Carsten Schulte as Marine Head
• Updated Bond Offering Details for Nykredit Realkredit A/S
• Revolutionizing Public Safety: Nokia and Motorola's Drone Tech
• Nippon Gases Chooses Juniper's AI Solutions for Enhanced Networking
• Recent Trading Activity Involves SP Group Shares Acquisition
• Discover Tineco's Exciting Holiday Offers on Smart Cleaners
• Transform Your Holiday Cleaning with Tineco FLOOR ONE Series
• GlobalPlatform Introduces SESIP for Upcoming Cybersecurity Framework
• Western Gate Champions DIA's Financing and Stock Restructuring
• Sylva Project Charts a Path to Next-Gen Telco Infrastructure
• Isotopia and LIVEKIDNEY.BIO Unite to Transform Lupus Care
• Dstny Welcomes Vladan Petrovic as Chief People Experience Officer
• Discover the New AI-Powered Patent Search Tool by Clarivate
• PQShield Bolsters Leadership Team To Drive Quantum Security
• Elevate Your Style with the Fashion Editor in My Talking Angela 2
• BOS and Tenstorrent Launch Revolutionary Automotive AI Solution
• DeerRun Expands Horizons with Innovative Fitness Solutions
• Sylva Project Develops Future-Proof Telco Cloud Infrastructure
• Dstny Appoints Vladan Petrovic as Chief People Experience Officer
• Careverse Takes Center Stage at Medical AI Conference 2024
• China: The Driving Force Behind Global Trade Expansion
• Seplat Energy Completes Major Acquisition of MPNU from ExxonMobil